Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?

Bone Marrow Transplant. 2019 Jun;54(6):913-916. doi: 10.1038/s41409-018-0390-3. Epub 2018 Nov 9.

Authors

John L Vaughn¹, Qiuhong Zhao², Narendranath Epperla², Marcin Puto³, Julianna Roddy³, Patrick Elder², William Blum⁴, Rebecca Klisovic⁴, Samantha Jaglowski², Sam Penza², Basem William², Leslie Andritsos², Jonathan E Brammer², Craig Hofmeister⁴, Yvonne Efebera², Don Benson², Steven Devine⁵, Spero Cataland², Sumithira Vasu⁶

Affiliations

¹ Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
² Division of Hematology, The Ohio State University, Columbus, OH, USA.
³ Department of Pharmacy, James Cancer Hospital, The Ohio State University, Columbus, OH, USA.
⁴ Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
⁵ National Marrow Donor Program, Minneapolis, MN, USA.
⁶ Division of Hematology, The Ohio State University, Columbus, OH, USA. sumithira.vasu@osumc.edu.

PMID: 30413812
DOI: 10.1038/s41409-018-0390-3

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Hematopoietic Stem Cell Transplantation / adverse effects*
Hematopoietic Stem Cell Transplantation / methods
Humans
Survival Analysis
Thrombotic Microangiopathies / etiology*
Thrombotic Microangiopathies / mortality
Thrombotic Microangiopathies / therapy*
Transplantation Conditioning / adverse effects*
Transplantation Conditioning / methods

Grants and funding

P30 CA016058/CA/NCI NIH HHS/United States